Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France.
Research context
Amoéba S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Amoéba S.A is currently in a long term downtrend where the price is trading 47.6% below its 200 day moving average.
From a valuation standpoint, the stock is 1626.8% more expensive than other stocks from the Basic Materials sector with a price to sales ratio of 453.9.
Finally, its free cash flow fell by 7.8% to $-808K since the same quarter in the previous year.
Based on the above factors, Amoéba S.A gets an overall score of 0/5.